Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its second quarter of fiscal year 2025 on Tuesday 19, 2024. A news release ...

Medtronic announced new long-term data from the SPYRAL HTN-ON MED clinical trial of the company’s Symplicity Spyral renal ...

A lawsuit against pulse oximeter manufacturers and distributors is starting to create change. But experts say the FDA needs ...

Medtronic and Recor Medical, Inc. (and its parent company, Otsuka Medical Devices Co., Ltd.) separately and independently ...

Medtronic has issued a second alert letter to patients regarding shortened battery life of the MiniMed 600 and 700 series insulin pumps. The affected products include the MiniMed 630G, 670G, 770G ...

Copyright © 2024 MarketWatch, Inc. All rights reserved.

The Affera mapping and ablation system with the Sphere-9 catheter [Images courtesy of Medtronic] Medtronic (NYSE:MDT) today said it received FDA approval for its Affera mapping and ablation system ...

Medtronic plc added a second U.S. FDA pulsed field ablation (PFA) device approval to its scorecard with the agency’s greenlight for its Affera mapping and ablation system with the Sphere-9 catheter.